Please assess the completion status of the following clinical trial:

Trial Title: A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM who are treated with metformin and/or diet and exercise~* HbA1c greater than or equal to 7% and less than or equal to 10.5%~* Total body weight \>50 kg (110 lb) with BMI 24.5 to 45.4 kg/m\^2~Exclusion Criteria:~* Any condition possibly affecting drug absorption~* Diagnosis of Type 1 diabetes~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of screening~* Any malignancy not considered cured~* Personal or family history of MTC or MEN2, or participants with suspected MTC~* Acute pancreatitis or history of chronic pancreatitis~* Symptomatic gallbladder disease~* Known medical history of active proliferative retinopathy and/or macular edema~* Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis~* Known history of HIV~* Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)~* Clinically relevant ECG abnormalities~* Positive urine drug test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-06882961 2.5 milligrams (mg) (Type: EXPERIMENTAL): None
- PF-06882961 10 mg (Type: EXPERIMENTAL): None
- PF-06882961 40 mg (Type: EXPERIMENTAL): Participants will be titrated up to 2 weeks to reach desired dose level
- PF-06882961 80 mg (Type: EXPERIMENTAL): Participants will be titrated up to 4 weeks to reach desired dose level
- PF-06882961 120 mg (Type: EXPERIMENTAL): Participants will be titrated up to 6 weeks to reach desired dose level

Based on this trial design, predict the completion outcome and termination type (if applicable).